Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 2/20 | 0.49 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.46 |
| ▸ | TSPO | P30536 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.42 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.42 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.42 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3960798 | 0.93 | TRPM8 (0.49) | BCHETRPM8LPAR1LPAR2LTB4R2 | |
| SCHEMBL3964009 | 0.87 | TRPM8 (0.47) | TRPM8LTB4R2MEN1KMT2AUSP2 | |
| SCHEMBL3963030 | 0.86 | TRPM8 (0.64) | TRPM8ALDH1A1LMNASMN1; SMN2HSD17B10 | |
| SCHEMBL3967728 | 0.85 | PPARG (0.45) | TRPM8ALOX5 | |
| SCHEMBL3963799 | 0.81 | RAB9A (0.63) | TRPM8ALDH1A1LMNASMN1; SMN2KDM4E | |
| SCHEMBL3967934 | 0.81 | USP2 (0.44) | BCHELPAR1LPAR2USP2HSD17B10 | |
| SCHEMBL3961377 | 0.80 | TP53 (0.49) | TRPM8ALDH1A1LMNASMN1; SMN2MAPT | |
| SCHEMBL3963788 | 0.79 | TRPM8 (0.52) | TRPM8LTB4R2ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL3963642 | 0.79 | TRPM8 (0.53) | TRPM8MAPT | |
| SCHEMBL3960463 | 0.78 | PPARD (0.44) | TRPM8LTB4R2MAPTUSP2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7488844-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2009-02-10 | — | — | US | disclosed |
| US-20050282822-A1 | Therapeutic agents | ASTRAZENECA AB (SE) | 2005-12-22 | — | — | US | disclosed |
| US-20050148656-A1 | 3-(amino-oxo(alkyl, alkyloxy and alkylthio)phenyl) propanoic and propenoic acid derivatives; peroxisome proliferator-activated receptors agonists; dyslipidemias with or without insulin resisitance and associated metabolic disorders (metabolic syndrome) including obesity, hypertension, type 2 diabetes | ASTRAZENECA AB (SE) | 2005-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148656-A1 | 3-(amino-oxo(alkyl, alkyloxy and alkylthio)phenyl) propanoic and propenoic acid derivatives; peroxisome proliferator-activated receptors agonists; dyslipidemias with or without insulin resisitance and associated metabolic disorders (metabolic syndrome) including obesity, hypertension, type 2 diabetes | GPR119, PPARA, PPARG | BCHE 4358/4885TRPM8 2338/4885ALOX5 90/4885 |
| US-20050282822-A1 | Therapeutic agents | GPR119, LIPC, PNLIP | BCHE 2688/4885TRPM8 4071/4885ALOX5 590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.